Results 171 to 180 of about 515,543 (292)
Interaction and Effect Modification in Clinical and Epidemiological Studies: Part 38 of a Series on the Evaluation of Scientific Publications. [PDF]
Kowall B, Stang A, Rathmann W.
europepmc +1 more source
Methods to improve antibody–drug conjugate (ADC) treatment durability in cancer therapy are needed. We utilized ADCs and immune‐stimulating antibody conjugates (ISACs), which are made from two non‐competitive antibodies, to enhance the entry of toxic payloads into cancer cells and deliver immunostimulatory agents into immune cells.
Tiexin Wang +3 more
wiley +1 more source
Non-additive Measure in Economic Dynamics
openaire +2 more sources
Etoposide induces DNA damage, activating p53‐dependent apoptosis via caspase‐3/7, which cleaves PARP1. Dammarenediol II enhances this apoptotic pathway by suppressing O‐GlcNAc transferase activity, further decreasing O‐GlcNAcylation. The reduction in O‐GlcNAc levels boosts p53‐driven apoptosis and influences the Akt/GSK3β/mTOR signaling pathway ...
Jaehoon Lee +8 more
wiley +1 more source
Neighborhood-Level Social Vulnerability, Race and Ethnicity, and Stage at Diagnosis: A Population-Based Study of 12,957 Patients with Oral Cavity Cancer. [PDF]
Tortolero GA +5 more
europepmc +1 more source
Tumor mutational burden as a determinant of metastatic dissemination patterns
This study performed a comprehensive analysis of genomic data to elucidate whether metastasis in certain organs share genetic characteristics regardless of cancer type. No robust mutational patterns were identified across different metastatic locations and cancer types.
Eduardo Candeal +4 more
wiley +1 more source
A prior-sampling conditional variational autoencoder for neuroimaging normative modelling: Benchmarking deep learning against statistical approaches. [PDF]
Ho MP +5 more
europepmc +1 more source
Aptamers are used both therapeutically and as targeting agents in cancer treatment. We developed an aptamer‐targeted PLGA–TRAIL nanosystem that exhibited superior therapeutic efficacy in NOD/SCID breast cancer models. This nanosystem represents a novel biotechnological drug candidate for suppressing resistance development in breast cancer.
Gulen Melike Demirbolat +8 more
wiley +1 more source
Error-controlled non-additive interaction discovery in machine learning models. [PDF]
Chen W, Jiang Y, Noble WS, Lu YY.
europepmc +1 more source
Regular non-additive measure and Choquet integral
identifier:oai:t2r2.star.titech.ac.jp ...
openaire +1 more source

